Vaxart (NASDAQ:VXRT) Share Price Passes Below 200 Day Moving Average – What’s Next?

Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.74 and traded as low as $0.69. Vaxart shares last traded at $0.72, with a volume of 848,941 shares trading hands.

Vaxart Price Performance

The company’s fifty day moving average is $0.70 and its 200-day moving average is $0.74. The company has a market capitalization of $164.79 million, a PE ratio of -1.77 and a beta of 0.82.

Institutional Trading of Vaxart

Institutional investors have recently modified their holdings of the company. Millennium Management LLC boosted its position in shares of Vaxart by 110.8% in the 2nd quarter. Millennium Management LLC now owns 3,985,670 shares of the biotechnology company’s stock worth $2,660,000 after purchasing an additional 2,095,274 shares in the last quarter. Mesirow Financial Investment Management Inc. boosted its holdings in Vaxart by 100.0% in the third quarter. Mesirow Financial Investment Management Inc. now owns 40,000 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 20,000 shares in the last quarter. XTX Topco Ltd grew its stake in shares of Vaxart by 869.3% during the third quarter. XTX Topco Ltd now owns 136,466 shares of the biotechnology company’s stock worth $116,000 after acquiring an additional 122,387 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Vaxart by 15.8% during the third quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company’s stock worth $2,160,000 after acquiring an additional 346,725 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Vaxart during the fourth quarter valued at about $129,000. 18.05% of the stock is currently owned by institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.